Effects	0	7	O
of	8	10	O
spironolactone	11	25	B-Drug_or_compound
on	26	28	O
corneal	29	36	B-Multi-tissue_structure
allograft	37	46	I-Multi-tissue_structure
survival	47	55	O
in	56	58	O
the	59	62	O
rat	63	66	B-Organism
.	66	67	O

PURPOSE	69	76	O
:	76	77	O
Spironolactone	78	92	B-Drug_or_compound
has	93	96	O
recently	97	105	O
been	106	110	O
shown	111	116	O
to	117	119	O
have	120	124	O
suppressive	125	136	O
effects	137	144	O
on	145	147	O
several	148	155	O
immunoactive	156	168	O
and	169	172	O
proinflammatory	173	188	O
cytokines	189	198	O
.	198	199	O

In	200	202	O
this	203	207	O
study	208	213	O
,	213	214	O
we	215	217	O
investigated	218	230	O
the	231	234	O
effects	235	242	O
of	243	245	O
spironolactone	246	260	B-Drug_or_compound
on	261	263	O
the	264	267	O
prevention	268	278	O
of	279	281	O
corneal	282	289	B-Multi-tissue_structure
allograft	290	299	I-Multi-tissue_structure
rejection	300	309	O
in	310	312	O
a	313	314	O
MHC	315	318	B-Gene_or_gene_product
class	319	324	I-Gene_or_gene_product
I	325	326	I-Gene_or_gene_product
/	326	327	O
II	327	329	B-Gene_or_gene_product
mismatch	330	338	O
rat	339	342	B-Organism
corneal	343	350	B-Multi-tissue_structure
transplant	351	361	O
model	362	367	O
.	367	368	O

METHODS	369	376	O
:	376	377	O
Grafted	378	385	O
animals	386	393	O
for	394	397	O
corneal	398	405	B-Multi-tissue_structure
survival	406	414	O
analysis	415	423	O
were	424	428	O
assigned	429	437	O
to	438	440	O
receive	441	448	O
either	449	455	O
spironolactone	456	470	B-Drug_or_compound
suspension	471	481	O
(	482	483	O
orally	483	489	O
,	489	490	O
100	491	494	O
mg	495	497	O
/	497	498	O
kg	498	500	O
/	500	501	O
day	501	504	O
,	504	505	O
n	506	507	O
=	508	509	O
7	510	511	O
)	511	512	O
,	512	513	O
phosphate	514	523	B-Drug_or_compound
-	523	524	I-Drug_or_compound
buffered	524	532	I-Drug_or_compound
saline	533	539	I-Drug_or_compound
(	540	541	O
PBS	541	544	B-Drug_or_compound
,	544	545	O
orally	546	552	O
,	552	553	O
same	554	558	O
volume	559	565	O
as	566	568	O
spironolactone	569	583	B-Drug_or_compound
,	583	584	O
n	585	586	O
=	587	588	O
9	589	590	O
)	590	591	O
or	592	594	O
remained	595	603	O
untreated	604	613	O
(	614	615	O
n	615	616	O
=	617	618	O
16	619	621	O
)	621	622	O
.	622	623	O

Additional	624	634	O
grafted	635	642	O
rats	643	647	B-Organism
treated	648	655	O
with	656	660	O
spironolactone	661	675	B-Drug_or_compound
(	676	677	O
n	677	678	O
=	679	680	O
6	681	682	O
)	682	683	O
or	684	686	O
PBS	687	690	B-Drug_or_compound
(	691	692	O
n	692	693	O
=	694	695	O
8	696	697	O
)	697	698	O
were	699	703	O
sacrificed	704	714	O
on	715	717	O
day	718	721	O
12	722	724	O
for	725	728	O
quantitative	729	741	O
RT	742	744	O
-	744	745	O
PCR	745	748	O
analysis	749	757	O
for	758	761	O
mechanistic	762	773	O
studies	774	781	O
.	781	782	O

RESULTS	783	790	O
:	790	791	O
Mean	792	796	O
(	797	798	O
+	798	799	O
/	799	800	O
-	800	801	O
SEM	801	804	O
)	804	805	O
graft	806	811	B-Multi-tissue_structure
survival	812	820	O
was	821	824	O
significantly	825	838	O
prolonged	839	848	O
in	849	851	O
animals	852	859	O
receiving	860	869	O
spironolactone	870	884	B-Drug_or_compound
(	885	886	O
14	886	888	O
.	888	889	O
9	889	890	O
+	891	892	O
/	892	893	O
-	893	894	O
2	895	896	O
.	896	897	O
0	897	898	O
days	899	903	O
)	903	904	O
compared	905	913	O
with	914	918	O
both	919	923	O
PBS	924	927	B-Drug_or_compound
-	927	928	O
treated	928	935	O
(	936	937	O
12	937	939	O
.	939	940	O
3	940	941	O
+	942	943	O
/	943	944	O
-	944	945	O
1	946	947	O
.	947	948	O
2	948	949	O
days	950	954	O
,	954	955	O
p	956	957	O
=	958	959	O
0	960	961	O
.	961	962	O
007	962	965	O
)	965	966	O
and	967	970	O
untreated	971	980	O
controls	981	989	O
(	990	991	O
13	991	993	O
.	993	994	O
0	994	995	O
+	996	997	O
/	997	998	O
-	998	999	O
1	1000	1001	O
.	1001	1002	O
0	1002	1003	O
days	1004	1008	O
,	1008	1009	O
p	1010	1011	O
=	1012	1013	O
0	1014	1015	O
.	1015	1016	O
01	1016	1018	O
)	1018	1019	O
.	1019	1020	O

We	1021	1023	O
found	1024	1029	O
a	1030	1031	O
decrease	1032	1040	O
in	1041	1043	O
corneal	1044	1051	B-Multi-tissue_structure
neovascularization	1052	1070	O
in	1071	1073	O
spironolactone	1074	1088	B-Drug_or_compound
-	1088	1089	O
treated	1089	1096	O
rats	1097	1101	B-Organism
compared	1102	1110	O
with	1111	1115	O
the	1116	1119	O
PBS	1120	1123	B-Drug_or_compound
-	1123	1124	O
treated	1124	1131	O
group	1132	1137	O
,	1137	1138	O
although	1139	1147	O
the	1148	1151	O
difference	1152	1162	O
was	1163	1166	O
not	1167	1170	O
statistically	1171	1184	O
significant	1185	1196	O
.	1196	1197	O

Spironolactone	1198	1212	B-Drug_or_compound
affected	1213	1221	O
both	1222	1226	O
systemic	1227	1235	O
(	1236	1237	O
down	1237	1241	O
-	1241	1242	O
regulation	1242	1252	O
of	1253	1255	O
CD25	1256	1260	B-Gene_or_gene_product
+	1260	1261	O
cells	1262	1267	O
in	1268	1270	O
spleen	1271	1277	B-Organ
)	1277	1278	O
and	1279	1282	O
local	1283	1288	O
immune	1289	1295	O
response	1296	1304	O
(	1305	1306	O
up	1306	1308	O
-	1308	1309	O
regulation	1309	1319	O
of	1320	1322	O
IL	1323	1325	B-Gene_or_gene_product
-	1325	1326	I-Gene_or_gene_product
10	1326	1328	I-Gene_or_gene_product
in	1329	1331	O
cornea	1332	1338	B-Multi-tissue_structure
)	1338	1339	O
.	1339	1340	O

CONCLUSION	1341	1351	O
:	1351	1352	O
We	1353	1355	O
present	1356	1363	O
initial	1364	1371	O
results	1372	1379	O
demonstrating	1380	1393	O
anti	1394	1398	O
-	1398	1399	O
inflammatory	1399	1411	O
effects	1412	1419	O
of	1420	1422	O
spironolactone	1423	1437	B-Drug_or_compound
.	1437	1438	O

